ABOUT US

About Ai Wei's Creatures

-- Organ-chip application full-scene solution provider

Jiangsu Aiwei Biotechnology Co., Ltd. (AVATARGET) was established in 2021. It is an innovative technology company focusing on the research and development and production of human organ chips and life science equipment. Ai Wei's core technology has been transformed into the organ chip research team of Southeast University, and the technological achievements have been successfully applied in scientific research scenarios such as new drug research and development, precision medicine, disease modeling, and beauty safety evaluation. At present, Ai Wei has reached in-depth cooperation with well-known domestic and foreign pharmaceutical companies, many hospitals, research institutions and universities to continue to promote the application of organ chips in more medical device fields and help the rapid development of life sciences.

2

Big

R & D Laboratory

20

+

Products and Applications

10

%

Doctor's percentage

65

%

Proportion of R & D personnel

2024-03

2024-03

2024-01

2023-08

2023-05

2022-12

2022-08

2022-08

2022-06

2021-01

2021-01

2020-02

2020-02

2019-01

2018-01

2013-01

2011-01

2010-01

The project of human organ-on-chip and multimodal precision measurement method construction selected as one of China’s Top 10 Science Advances in 2023
The project of human organ-on-chip and multimodal precision measurement method construction selected as one of China’s Top 10 Science Advances in 2023
The Center of NMPA issued the Technical Guidelines on Non-clinical Studies of Human Stem Cell-based Products, which explicitly includes new technologies such as organoid into the evaluation models for non-clinical studies of human stem cell-based
The first space OoC culture experiment in Chinese’s space station, also the first international Taikonaut-Blood-Vessels-on-a-Chip study
HRS-1893 tablets were approved for clinical trials, which is the first breakthrough of organoid data outside the realm of CGT drugs
U.S. President Biden signed into law the FDA Modernization Act 2.0, eliminating federal mandatory requirement for animal testing for new and generic drugs
General Technical Requirement of Skin-on-a-chip, China’s first draft technical standard for OoCs, was published
For the first time, the FDA had approved the clinical trial of an investigational therapy based solely on preclinical efficacy data obtained in human OoC studies
The U.S. House of Representatives passed the Food and Drug Amendments of 2022, which includes OoCs and Microphysiological Systems (MPSs) as independent systems for evaluating drugs in non-clinical trials
Organoid research has been approved as a key special project of the National Key R&D Program in China’s 14th Five-Year Plan
The Center of NMPA published the Technical Guidelines on Nonclinical Studies of Genetically Modified Cell Therapy Products, allowing for the use of cell- and tissue-based models to provide useful supplemental information for efficacy and safety evaluation
Southeast University in China developed a bronchial-lung-on-chip that could be used for the evaluation of COVID-19 infections and treatments, and applied it at the Jiangsu Provincial Center for Disease Control and Prevention
FDA used lung-on-chips to evaluate the safety of COVID-19 vaccines and their protective immunity against SARS-CoV-2
The U.S. Environmental Protection Agency (EPA) has announced that it will stop funding all mammal testing by 2035
California has banned cosmetic testing on animals
The EU has imposed a ban from testing finished cosmetic products and cosmetic ingredients on animals and from marketing finished cosmetic products and ingredients which were tested on animals
The U.S. government was the first to announce the launch of a human body-on-a-chip program, aiming to develop human body-on-a-chips for new drug development and toxicity prediction
Harvard University successfully developed the human lung-on-a-chip

Core Team

Enterprise management and innovation technology strength coexist

Picture Name

Gu Zhongze

Chief Scientist

Doctor/Professor/Changjiang Scholar/National Outstanding Youth
 

Fellow of the American Academy of Medical and Biological Engineering, Chief Scientist of the Provincial Innovative Medical Device Industry Chain, Director of the National Key Laboratory of Digital Medical Engineering, the only Chinese director of the 16 founding directors of the International Society of Microphysiological Systems, and the Chinese Society of Biomedical Engineering Class and Organ Chip The chairman of the branch won the first prize of natural science from the Ministry of Education, and the highest prize in the National Ministry of Science and Technology Subversive Technology Competition.

Picture Name

Ge Jianjun

Chairman Ai Wei

Southeast University Junior Class
Nanjing University MBA

 

Vice president of the top 100 private enterprises, more than 30 years of technical and management work experience, including 25 years of senior management of large and medium-sized enterprises and institutions, expert judges of the Innovation and Entrepreneurship Competition of the Department of Science and Technology and Human Resources and Social Security of Jiangsu Province, and entrepreneurial mentors of many institutions have been selected The "List of National Scientific and Technological Achievements Research and Development Heritors" awarded by the National Science and Technology Commission.

Picture Name

Sha Li Feng

Chief Executive Officer (CEO)

PhD, The Chinese University of Hong Kong

 

Previously worked in Shenzhen Meirui/Suzhou Changguanghua Medical,Nearly 20 years of IVD industry experience, presided over the development and industrialization of a variety of medical devices.,Presided over the special project of transformation of scientific and technological achievements in Jiangsu Province,Second Prize of National Science and Technology Progress Award,Second Prize of Beijing Science and Technology Progress Award,Second prize for scientific and technological progress in Suzhou.

Picture Name

Chen ZaoZao

Chief Technology Officer (CTO)

Southeast University Supreme Good Young Scholar/Associate Researcher

 

PhD in Cell Biology, University of North Carolina, USA,Postdoctoral/Associate Researcher, Duke University and Columbia University, USA,Chinese Society of Biomedical Engineering Organoids andSecretary-General of Organ Chip Branch,As a major member, more than 50 SCI/EI papers have been published in the two US organ chip 1,Il and II phases of NIH funding.,A number of national key projects and project leaders.

Picture Name

Xu Yuan

Deputy General Manager (COO)

Doctor of Science, Chinese Academy of Sciences

 

More than ten years of management and operation experience in multinational large and medium-sized enterprises

Organize research and development of the first domestic NGS intelligent sample processing system with independent intellectual property rights, Falcon2.0

Former Chief Operating Officer and Vice President of Beijing Nuohe Zhiyuan Technology Co., Ltd.

Picture Name

Vision

Picture Name

Become the leader of the organ chip


Picture Name

Mission

Picture Name

Care for life with "core"


Picture Name

Values

Picture Name

Seeking truth, innovation, hard work, win-win cooperation


2025年

2025.11,Avatarget's skin chip technology was selected as an advanced technological innovation achievement in the light industry during the 14th Five-Year Plan period, making it the only project selected in the fragrance and cosmetics sector.

2025年

2025.09 Avatarget skin chip was selected as one of the top ten technological advancements in China's cosmetics industry in 2025.

2025年

2025.07 Professors Gu Zhongze and Chen Zaozao have been appointed to important positions in the International Union of Microphysiological Systems.

2025年

2025.06 Avatarget empowers the official release of the world's first DILI large-scale model.

2025年

2025.05 Avatarget's human organ-on-a-chip project won the 2025 VBEF "Best Biotechnology Innovation Product" award.

2025年

2025.02 Avatarget has been selected for the 2024 Suzhou "Unicorn" Cultivation Enterprise List.

2025年

2025.01 Avatarget was selected as an outstanding innovative case in Arterial Network's "Innovative Drugs and Supply Chain White Paper".

2024年

2024.12 Avatarget was selected as a "Jiangsu Provincial Postdoctoral Innovation Practice Base" and was selected as one of the "Seven Major Advances in Space Human Research".

2024年

2024.11 Avatarget Participates in Release of Expert Consensus on Liver Organ-Chips for Drug Safety Prediction; "Multimodal Precision Measurement Technology and Application of Human Organ-Chips" Wins Second Prize in Golden Bridge Award Projects

2024年

2024.10 The first organ-on-a-chip technology standard in China, "General Technical Requirements for Skin Chips," which I helped draft, has been officially released.

2024年

2024.09 Avatarget Biotech Selected for Jiangsu's List of Potential Unicorn Companies

2024年

2024.03 The project on the development of human organ-on-a-chip and multimodal precision measurement methods was selected as one of the "Top 10 Advances in Life Sciences in China in 2023".

2024年

2024.02 Awarded Suzhou High-tech Zone's 2023 High-Growth Innovative Enterprise

2023年

2023.12 Recognized as a National High-tech Enterprise; completed a Pre-A+ round of financing led by Tongfang Investment.

2023年

2023.11 Selected for the 2023 Jiangsu Potential Unicorn Companies List; Huawei's Pangu + Organ Chip: The World's First Large-Scale Medical Model for Human Organ Chips Released

2023年

2023.08 The first domestic experiment of cultivating organ-on-a-chip in space was successfully completed on the Chinese space station, and it is also the world's first study of artificial blood vessel tissue-on-a-chip in space.

2023年

2023.05 In collaboration with Hengrui, China's first new drug using organ-on-a-chip data has been approved for clinical trials.

2022年

2022.10 Organ-on-a-chip project selected for the Ten-Year Achievement Exhibition of Science and Technology Innovation by Overseas Chinese

2022年

2022.06 Completed Pre-A round financing led by Rehabilitation Capital

2022年

2022.03 Winner of the highest award at the first National Disruptive Technology Innovation Competition

about

Patent Layout

Through the transformation of production, teaching and research and independent research and development, Ai Wei has laid out nearly 100 patents, of which 50% of the invention patent applications, patent distribution covers organ chips, biological models and materials, instruments and equipment and software and other core products. The Pre-A round of financing led by rehabilitation capital has been completed, which is nearly 100 million yuan.

 

As China's organ chip model standard, Ai Wei's skin chip technology has been approved by the National Standardization Management Committee.

Ava’target (Alpha Target)止于至善

The human organ chip project has successfully crossed the last kilometer from the research and development end to the application end.

Avatar'get (Avatar Get) alternative experiment

Build the whole industry chain ecosystem of organ chip technology, insight into the mystery of life science, help medical science and technology reform, and meet the individual needs of patients.

Value recognition

Since its establishment, Ai Weid's team has been selected into the list of potential unicorn companies in Jiangsu Province, and won the "First National Disruptive Technology Innovation Competition Finals Award", "First Prize of the Ninth Overseas Chinese Contribution Award", and "High-tech Zone Entrepreneurship Leading Talent Enterprise" "Second Prize of Jiangsu Information Consumption Competition", "Gusu Entrepreneurship Leading Talent Enterprise", "China Patent Excellence Award" and other awards, it has made achievements such as "China's organ chip for entering the space station and carrying out scientific experiments", "China's organ chip for applying for new drug IND" and "China's organ chip technical standards for project approval", and has completed the Pre-A round of financing of nearly 100 million yuan led by rehabilitation capital.

about
Picture Name

China's first

Organ-on-a-chip to enter the space station and perform scientific experiments

Picture Name

China's first

Organ-chip for application of new drug IND

Picture Name

China's first

Technical standard for organ-on-a-chip

Partners

Walk with you, side by side with success, we are here waiting for you to create the future together!

北京协和医院

北京协和医院

中源生物

中源生物

香港大学

香港大学

301解放军总医院

301解放军总医院

东南大学

东南大学

鼓楼医院

鼓楼医院

恒瑞

恒瑞

华中科技大学

华中科技大学

集萃药康

集萃药康

江苏省疾病预防控制中心

江苏省疾病预防控制中心

江苏省人民医院

江苏省人民医院

江苏省肿瘤医院

江苏省肿瘤医院

凯基生物

凯基生物

南京大学

南京大学

南京正大天晴

南京正大天晴

赛赋医药

赛赋医药

苏大附一医院

苏大附一医院

泰格医药

泰格医药

先声药业

先声药业

昭衍

昭衍

Honor

  • 1(1699511581746).jpg

    第一届江苏省信息消费大赛总决赛产品创新二等奖

  • 2(1699511613733).jpg

    中国创新创业大赛江苏赛区优秀企业

  • 3(1699511633594).jpg

    中国第一个进入空间站并实施科学实验的器官芯片

  • 4(1699511651809).jpg

    中国第一个器官芯片技术标准

  • 5(1699511666660).jpg

    中国第一个用于申请新药IND的器官芯片